Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain

NCT01864265 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Certolizumab Pegol
DRUG: Placebo

Sponsor

University of Erlangen-Nürnberg Medical School